Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly’s Mirikizumab Shows Superiority Vs. Cosentyx In Psoriasis

Executive Summary

Lilly plans to file the anti-IL-23 antibody for approval in psoriasis based on two Phase III trials. The latest data head-to-head against IL-17 inhibitor Cosentyx may guide physicians on how to treat patients.

You may also be interested in...



Lilly’s Bio-Medicines Portfolio Grows To Offset Pressures In Key Markets

Lilly Bio-Medicines president Ilya Yuffa oversees newer products in competitive therapeutic areas and drug classes, but additional indications and new therapies within the group’s immunology, pain and neuroscience focus areas will capitalize on the group’s existing commercial expertise. 

Lilly’s Mirikizumab Hits All Marks In First Phase III Study For UC

Antibody targeting IL-23p19 yields clinical remission of ulcerative colitis after 12 weeks in the Phase III LUCENT-1 study. It also met all secondary endpoints, including reduction of bowel urgency.

Lilly Points To Six-Month Growth Instead Of Pandemic Impacted Q2

Lilly argues the overall trend is positive, although the second quarter was down. Trial successes with Verzenio, Trulicity, Jardiance and mirikizumab offer additional growth potential.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel